Understanding how pre- and probiotics affect the gut microbiome and metabolic health.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing physiological mechanisms and clinical perspectives without systematic review or meta-analysis
PubMed 38809510 · doi:10.1152/ajpendo.00054.2024
What was done
This paper reviewed existing literature on the role of the gut microbiota in metabolic health and disease, examining the physiological mechanisms and potential therapeutic effects of prebiotics and probiotics on metabolic disorders.
What was found
No numerical results or effect sizes were reported in the abstract. The authors report that gut dysbiosis links to type 2 diabetes, obesity, and cardiovascular disease via impaired gut barrier function, endotoxemia, and toll-like receptor-mediated inflammation. Fermentation-derived short-chain fatty acids modulate anti-inflammatory pathways, and prebiotics and probiotics (specifically Lactobacillus and Bifidobacterium strains) are noted to improve metabolic outcomes, including glycemic control.
Why it matters
It highlights the mechanistic link between gut barrier integrity, short-chain fatty acid production, and systemic metabolic regulation, summarizing how targeted microbiome interventions might aid metabolic disease management.
Limits
The abstract provides no primary human data, quantitative metrics, or systematic search methodology. The authors emphasize that substantial study variability and strain-specific effects currently limit generalizable clinical applications.
Cited by
- supports Dietary fibers generally increase beneficial gut microbes such as Bifidobacterium and Lactobacillus, which produce short-chain fatty acids that support immune function.